Diffuse Lung Disease
-
Study identifies key environmental exposures associated with risk of interstitial lung disease
Bradford C. Bemiss, MD, MSc, said the findings underscore the importance of asking patients about potential workplace inhalation exposures.
-
The respiratory toll of traffic pollution in obstructive lung disease and ILD
Traffic-related air pollution reduces lung function and worsens cases of COPD and ILD. Pulmonologists should assess patient exposure and advise on mitigation strategies.
-
Nerandomilast opens the door for potential monotherapy, add-on therapy for pulmonary fibrosis
Positive results from the FIBRONEER trials of nerandomilast in IPF and PPF have sent the phosphodiesterase 4B inhibitor to the FDA for marketing approval. If approved, nerandomilast would be the first new antifibrotic agent for ILD in more than a decade.
-
Optimizing lung transplant care
In the evolving landscape of transplant medicine, APPs are proving to be indispensable through their clinical expertise, consistency, and adaptability across care settings.
-
Current standards in donor lung procurement and preservation
Review the American Association for Thoracic Surgery’s expert consensus guidelines for improving standardization in key areas of lung acquisition.
-
New data confirms ILD as lung cancer risk factor
Bradford C. Bemiss, MD, and Claudia Henschke, PhD, MD, said the study clearly shows patients with interstitial lung disease have an increased risk of lung cancer.
-
Varenicline found effective for nicotine vaping cessation in youth
Researcher A. Eden Evins, MD, said she was surprised by the ineffectiveness of behavioral therapy alone.
-
Get informed and involved with smoking cessation strategies, advocacy
Sessions will equip attendees with the latest information about the health consequences of e-cigarettes and cannabis. Because the landscape has evolved so much recently, misconceptions are common—even among clinicians, said Evan Stepp, MD, FCCP.
-
ORCA-3 replicates strong tobacco cessation results for cytisinicline
The ORCA-3 trial demonstrated that cytisinicline, a reformulated compound, significantly outperformed placebo by nearly six times in helping adults who smoke to quit.
-
Update on the evaluation and management of interstitial lung abnormalities
New guidelines from ATS outline the screening and follow-up procedures for interstitial lung abnormalities as well as define who is at higher risk for progressing to ILD.
-
Admilparant phase 2 results raise hopes for combination treatment in pulmonary fibrosis
Fernando Martinez, MD, FCCP, said he expects the treatment options for fibrotic lung disease will soon become more complex—in a good way—as more effective therapies become available.
-
GOLDen handcuffs: Beyond spirometry in COPD
When it comes to diagnosing COPD, clinicians must look beyond spirometry and physiology to see a patient fully.
